select a format

Single User License
USD 1500 INR 97530
Site License
USD 3000 INR 195060
Corporate User License
USD 4500 INR 292590

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Immunicum AB-Product Pipeline Review-2015

Immunicum AB-Product Pipeline Review-2015


  • Products Id :- GMDHC07736CDB
  • |
  • Pages: 25
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Immunicum AB-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Immunicum AB-Product Pipeline Review-2015', provides an overview of the Immunicum AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunicum AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Immunicum AB including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Immunicum AB's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Immunicum AB's pipeline products

Reasons To Buy

Evaluate Immunicum AB's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Immunicum AB in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Immunicum AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Immunicum AB and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunicum AB

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Immunicum AB and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Immunicum AB Snapshot 4

Immunicum AB Overview 4

Key Information 4

Key Facts 4

Immunicum AB-Research and Development Overview 5

Key Therapeutic Areas 5

Immunicum AB-Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products-Monotherapy 8

Immunicum AB-Pipeline Products Glance 9

Immunicum AB-Clinical Stage Pipeline Products 9

Phase II Products/Combination Treatment Modalities 9

Phase I Products/Combination Treatment Modalities 10

Immunicum AB-Early Stage Pipeline Products 11

IND/CTA Filed Products/Combination Treatment Modalities 11

Preclinical Products/Combination Treatment Modalities 12

Immunicum AB-Drug Profiles 13

Intuvax 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

Cell Therapy for Cancer 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Subcuvax 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Immunicum AB-Pipeline Analysis 19

Immunicum AB-Pipeline Products by Route of Administration 19

Immunicum AB-Pipeline Products by Molecule Type 20

Immunicum AB-Recent Pipeline Updates 21

Immunicum AB-Locations And Subsidiaries 23

Immunicum AB-Locations And Subsidiaries 23

Head Office 23

Appendix 24

Methodology 24

Coverage 24

Secondary Research 24

Primary Research 24

Expert Panel Validation 24

Contact Us 24

Disclaimer 25

List of Tables

Immunicum AB, Key Information 4

Immunicum AB, Key Facts 4

Immunicum AB-Pipeline by Indication, 2015 6

Immunicum AB-Pipeline by Stage of Development, 2015 7

Immunicum AB-Monotherapy Products in Pipeline, 2015 8

Immunicum AB-Phase II, 2015 9

Immunicum AB-Phase I, 2015 10

Immunicum AB-IND/CTA Filed, 2015 11

Immunicum AB-Preclinical, 2015 12

Immunicum AB-Pipeline by Route of Administration, 2015 19

Immunicum AB-Pipeline by Molecule Type, 2015 20

Immunicum AB-Recent Pipeline Updates, 2015 21

List of Figures

Immunicum AB-Pipeline by Top 10 Indication, 2015 6

Immunicum AB-Pipeline by Stage of Development, 2015 7

Immunicum AB-Monotherapy Products in Pipeline, 2015 8

Immunicum AB-Pipeline by Top 10 Route of Administration, 2015 19

Immunicum AB-Pipeline by Top 10 Molecule Type, 2015 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Immunicum AB; Immunicum AB-Key Therapeutics; Immunicum AB-Pipeline Overview and Promising Molecules; Immunicum AB-News; Immunicum AB-Latest Updates; Immunicum AB-Pipeline; Immunicum AB-Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com